Delirium as an Adverse Reaction to BNT162b2 mRNA Vaccine from Pfizer Inc., and BioNTech
The spike-protein severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine has developed different adverse reactions. Still, delirium has not been reported in a low-risk patient, and it is important to consider it and recognize it as a possibility in all severity risk patients. We presen...
Saved in:
Main Authors: | Lilia M. Sierra Galan, Raquel Cohen Shaooli |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
Series: | APIK Journal of Internal Medicine |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/ajim.ajim_66_21 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case report: Development of anxiety symptoms after receiving the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine: a case series
by: Maris Taube, et al.
Published: (2025-01-01) -
Delayed-onset anaphylaxis after first dose of Pfizer-BioNTech COVID-19 vaccine
by: Carol Tay, et al.
Published: (2023-09-01) -
A Rare Cutaneous Manifestation: Leukocytoclastic Vasculitis after Pfizer-BioNTech COVID-19 Vaccination
by: Yaritza Serrano Gomez, et al.
Published: (2022-01-01) -
Comparison of IgG and Neutralizing Antibody Response After Pfizer BioNTech COVID-19 Vaccine Among Iraqi Individuals
by: Najat Saeed Hussein, et al.
Published: (2023-06-01) -
Distinct response patterns of endothelial markers to the BNT162b2 mRNA COVID-19 booster vaccine are associated with the spike-specific IgG antibody production
by: Beatriz Castro-Robles, et al.
Published: (2025-01-01)